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Abstract
Background/Aims: In this corollary analysis of the EXCITE study, we looked at possible 
differences in baseline risk factors and mortality between subjects excluded from the 
trial because non-eligible (n=216) or because eligible but refusing to participate (n=116). 
R. Baggetta and D. Bolignano contributed equally to the present work.
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Introduction
Precise definition of the population investigated in clinical trials and in well-planned 
observational studies is fundamental to understand the potential applicability of findings in 
these studies in clinical practice. The CONSORT (Consolidated Standards of Reporting Trials) 
document recommends a specific diagram for describing the flow of participants through 
the main phases of clinical trials [1], from eligibility to actual enrollment and follow-up. 
By the same token, a similar approach has been recommended for observational studies 
by STROBE, another document produced under the aegis of the EQUATOR (Enhancing 
the QUAlity and Transparency Of health Research) initiative. The importance of accurate 
reporting of the selection process of subjects enrolled into a trial is of obvious relevance 
for the generalizability of findings in the same trial. However, outcome data in subjects 
screened but not enrolled in clinical trials (as not eligible or as refusing to provide consent 
to participate) have received very little attention and we have been unable to identify even 
a single study focusing on this issue. The problem appears of particular relevance in trials 
testing exercise programs, i.e. trials which selects individuals with an inherently lower 
risk profile, i.e. with a degree of fitness allowing a physical exercise program. We hereby 
report a study corollary to the EXerCise Introduction To Enhance performance in dialysis 
(EXCITE) study, i.e. a multicentric, randomized controlled clinical trial on the effectiveness of 
exercise for improving physical performance and the quality of life and for reducing adverse 
clinical outcomes (mortality, cardiovascular events and hospitalizations) in dialysis patients 
(NCT01255969). We specifically designed this study to investigate differences in baseline 
risk factors and their influence on the overall survival in non-eligible patients and in eligible 
patients who declined the invitation to participate into the trial.
Patients and Methods
The study protocol was in conformity to the ethical guidelines of our institution and informed consent 
was obtained from each participant.
Patients
This is a study corollary to the EXerCise Introduction To Enhance performance in dialysis (EXCITE) 
study. More detailed information about this trial are available in ClinicalTrials.gov (NCT01255969). In this 
study we investigated the differences in baseline risk factors and their influence on the incidence rate of 
mortality in non-eligible patients (n=216; 90% on HD) and eligible patients who did not give the informed 
Methods: Baseline characteristics and mortality data were recorded. Survival and independent 
predictors of mortality were assessed by Kaplan-Meier and Cox regression analyses. Results: 
The incidence rate of mortality was higher in non-eligible vs. eligible non-randomized patients 
(21.0 vs. 10.9 deaths/100 persons-year; P<0.001). The crude excess risk of death in non-
eligible patients (HR 1.96; 95% CI 1.36 to 2.77; P<0.001) was reduced after adjustment for 
risk factors which differed in the two cohorts including age, blood pressure, phosphate, CRP, 
smoking, diabetes, triglycerides, cardiovascular comorbidities and history of neoplasia (HR 
1.60; 95% CI 1.10 to 2.35; P=0.017) and almost nullified after including in the same model also 
information on deambulation impairment (HR 1.16; 95% CI 0.75 to 1.80; P=0.513). Conclusions: 
Deambulation ability mostly explains the difference in survival rate in non-eligible and eligible 
non-randomized patients in the EXCITE trial. Extending data analyses and outcome reporting 
also to subjects not taking part in a trial may be helpful to assess the representability of the 
study population.
 Copyright © 2014 S. Karger AG, Basel
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in non-eligible patients (interquartile range 1.2 to 4.0 years) and 4.0 years in eligible patients unwilling 
to participate into the trial (interquartile range 2.3 to 4.0 years). During follow-up, death was accurately 
recorded. Each death was reviewed and assigned an underlying cause by a panel of 5 physicians. As a part 
of the review process, all available medical information about each death were collected. This information 
always included study and hospitalisation records. In the case of an out-of-hospital death family members 
were interviewed by telephone to better ascertain the circumstances surrounding death. 
Statistical analysis
Data were expressed as mean ± standard deviation (normally distributed data), median and inter-
quartile range (non-normally distributed data) or as per cent frequency (categorical data), and the 
comparisons among groups were made by One Way ANOVA, Kruskal-Wallis Test and Chi Square Test, as 
appropriate. 
In each study cohort, the independent predictors of mortality were identified by Kaplan-Meier 
survival analysis and by univariate and multivariate Cox regression models. Tested variables included age, 
gender, smoking, diabetes, blood pressure, total cholesterol, triglycerides, haemoglobin, albumin, calcium, 
phosphate, C-Reactive Protein, history of neoplasm, myocardial infarction, stroke, TIA, angina episodes, 
arrhythmia, peripheral vascular disease, and heart failure. We built-up multiple Cox regression models 
specific to each study cohort, by introducing into these models all variables which were related to all-cause 
mortality with P<0.10. To assess whether the observed difference in the death risk among the two study 
cohorts (i.e. non-eligible patients and eligible non-randomized patients) could be explained by differences 
in baseline risk factors (Table 1), we performed a multiple Cox regression analysis in the whole study 
population (n=648) including the group (cohort) variable and a series of risk factors which were related 
Table 1. Main demographic, clinical and biochemical characteristics of patientsconsent to take part into 
the EXCITE trial (n=116; 
84% on HD). Deambula-
tion ability was catego-
rized as independent, as-
sisted or total inability to 
deambulate (bedridden 
or wheel-chaired). The 
main demographic, clini-
cal and biochemical char-
acteristics of patients 
included in this study are 
given in Table 1. 
L a b o r a t o r y 
measurements
Blood sampling was 
performed during a mid-
week day (short dialysis 
interval). Serum choles-
terol, albumin, calcium, 
phosphate, C-Reactive 
Protein (CRP) and hae-
moglobin measurements 
were made using stand-
ard methods in the rou-
tine clinical laboratory.
Follow up
After the initial as-
sessment, the median 
follow-up was 2.9 years 
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(with P<0.10) to mortality in each study cohort (Table 2) and/or differed (with P<0.10) among the two 
cohorts (Table 1). By this strategy we constructed models of adequate statistical power (i.e. at least 10 
deaths for each variable into the models). In the survival analysis, data were expressed as hazard ratio, 95% 
confidence interval and P value. 
The explained variation in mortality attributable to single variables was calculated by the method 
proposed by Hosmer and Lemeshow [2]. Statistical analysis was performed by using a standard statistical 
package (SPSS for Windows, Version 20, Chicago, Illinois, USA.
Results
The source population of the EXCITE study included 648 patients with ESKD. Among 
these, 216 patients were excluded because they did not meet inclusion criteria (33%), 116 
patients were eligible but did not give the informed consent (18%) and the remaining 316 
patients were randomized (49%). Most non-eligible patients (64%) did not deambulate 
autonomously and/or needed to be assisted in everyday life. Eligible patients non-
participating into the study were significantly younger and displayed a lower proportion of 
patients with angina, arrhythmia, heart failure and TIA as compared to non-eligible patients. 
Circulating levels of phosphate and the prevalence of smokers and hypertensive patients 
were higher in eligible non-randomized patients than in non-eligible patients (Table 1). 
Circulating levels of C-Reactive Protein (CRP) and the prevalence of peripheral vascular 
disease were higher in non-eligible patients than in eligible patients who did not give the 
informed consent (Table 1). 
Predictors of mortality in eligible non-randomized patients and in ineligible patients
During the follow-up period, the number of deaths was 119 in non-eligible patients 
(55%) and 41 in eligible non-randomized (35%) patients. In non-eligible patients, age, 
Table 2. Univariate Cox regression analyses in the two study cohorts. Categories grading ambulation im-
pairment are listed in Table 1
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triglycerides, phosphate, CRP, history of heart failure, history of peripheral vascular disease 
and deambulation degree (autonome, assisted or bedridden/wheelchaired) predicted death 
with formal statistical significance (p<0.05) while only age, history of arrhythmia and history 
of neoplasia associated significantly with the same outcome in eligible patients who did 
not enter into the trial (Table 2). Non-significant associations (p>0.05, p<0.10) with death 
were noted for smoking (Table 2). In multivariate analyses mortality was predicted only by 
age, triglycerides, CRP, degree of deambulation and history of heart failure in non-eligible 
patients (Table 3a) and only by age in eligible non-randomized patients (Table 3b). 
Comparison of survival in eligible non-randomized patients and in ineligible patients 
The incidence rate of mortality was substantially higher in non-eligible patients 
(incidence rate: 21.0 deaths/100 persons-year) than in eligible non-randomized patients 
(incidence rate: 10.9 deaths/100 persons-year) (Log rank test: χ2=13.85, p <0.001) (Fig. 
1a). To assess whether the difference in baseline risk factors could explain the difference 
in the death risk of the two study cohorts, we performed two multivariate analyses 
including the group variable of eligible and non-eligible patients (cohorts) and a series of 
risk factors which were related to mortality (with p<0.10) in each study cohort (Table 2) 
and/or differed (with p<0.10) among the two cohorts (Table 1). To estimate the impact 
of the degree of deambulation impairment on mortality we tested two models, the first 
excluding deambulation ability and the second including this co-variate. In the first model 
the crude difference in the mortality risk among the two cohorts (HR 1.96; 95% CI 1.36 
to 2.77; P<0.001) was reduced modestly (HR 1.60; 95% CI 1.10 to 2.35; P=0.017) (Fig.1b 
and Table 4). However, additional adjustement for deambulation almost nullified the excess 
risk of death seen in non-eligible patients (HR 1.16; 95% CI 0.75 to 1.80; P=0.513) (Fig.1c 
and Table 4). Of note, the explained variation in all-cause mortality was 33% for the model 
excluding and 38% for the model including the deambulation variable (P<0.0005). Thus, 
deambulation captures as much as the 13% in the explained variability in the risk of death. 
Discussion
This study corollary to a multicenter randomized, clinical trial testing the effect of 
physical exercise in dialysis patients shows that the mortality risk is twice higher in patients 
who were excluded from the trial than in eligible patients who did not accept to participate. 
Importantly, the mortality rate in this group (10.9 deaths/100 persons-year) was lower 
than the average mortality rate in the ERA-EDTA registry [3] and in the Italian registry of 
dialysis [4]. As expected, the two populations which remained external to the trial, i.e. the 
Table 3. Separate 
multiple Cox re-
gression models 
in non-eligible 
patients (a) and 
eligible non- ran-
domized patients 
(b)
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ineligible population and the population with sufficient fitness but unwilling to undergo 
the exercise program, showed several differences in baseline risk factors such as age, blood 
pressure, phosphate, CRP, smoking, diabetes, triglycerides, cardiovascular comorbidities and 
history of neoplasia. We hypothesized that these differences could explain the higher death 
risk of ineligible patients and tested this hypothesis by modeling death risk in an analysis 
where the two cohorts were nominally identified by a specific covariate. The proviso was 
that the inclusion of known risk factors differentiating the two cohorts should attenuate 
substantially or cancel out the excess death risk of unfit patients ineligible to the trial. 
However, in contrast to our working hypothesis, we found that adjustment for background 
risk factors only in limited part explained the between cohorts difference in mortality. 
This finding indicates that major risk factors fail to fully capture the higher probability of 
death in patients ineligible to clinical studies. Thus, the higher death rate in those patients 
must necessarily depend on unmeasured risk factors of paramount importance for human 
health. Most non-eligible patients (64%) did not deambulate autonomously or needed to be 
assisted, indicating that comorbidities limiting motor activity in everyday life mark a degree 
of severity that is unaccounted for by nominally defined, ungraded, major comorbidities like 
arrhythmia, heart failure, cerebro- and peripheral-vascular disease, ischemic heart disease 
and neoplasia. Indeed, when we introduced into the model deambulation impairment, the 
between cohorts difference in the risk of death almost disappeared (HR 1.16; 95% CI 0.75 
Fig. 1. Unadjusted and adjusted survival analyses in the two study groups (non-eligible and eligible non 
randomized patients).
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Table 4. Multivariate Cox regression analysis in the whole study population
to 1.80; P=0.513). This observation is of importance because physical performance and 
inability to deambulate are very rarely taken into account when describing the risk profile 
of dialysis patients in major clinical trials and observational studies in this population. For 
example, neither in the 4D [5], nor in the AURORA study [6], nor in the more recent EVOLVE 
trial [7], physical disability was an exclusion criterion but in none of these trials information 
on physical disability was given. About 1/3 (33%) of the source cohort of the EXCITE study 
had a relevant degree of physical impairment and it is likely that a similar proportion existed 
in the source populations of other trials in dialysis patients. The variability in mortality 
rate explained by unfitness to a simple exercise program is substantial and ignoring severe 
limitation in physical functioning may have a non trivial effect for the interpretation of the 
risk profile of patients included in clinical studies. However, as discussed, information on 
ambulatory ability is almost always omitted in trials in the dialysis population. Findings in 
this study represent a call for systematic reporting information on physical activity and/or 
(motor) ability in clinical trials and observational studies in this population. Indeed -well 
beyond classical risk factors, background co-morbidities and risk factors peculiar to end-stage 
renal disease- deambulation impairment explains a relevant proportion of the variability 
in mortality in ESKD. Furthermore, our findings suggest that extending outcome reporting 
and data analyses to the whole source population of clinical trials may provide relevant 
information to better frame the implications of the selection process applied to restrict the 
trial population to patients with well-defined demographic and clinical characteristics.
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